ERBB2 and gastric cancer: Before February 2023, there were up to six entities of biological agents (pertuzumab, trastuzumab emtansine, inetetamab, disitamab vedotin, trastuzumab deruxtecan, and margetuximab) on the market with indications for HER2-positive breast cancer and gastric cancer, akin to trastuzumab.